EUVIMEDEUVIMED entdecken
Scoping Review

Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review

Abedeh Rezaei iD, Amin Moqadami iD, Mohammad Khalaj-Kondori iD

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-05 · 397 (5) · 2835-2848

DOI: 10.1007/s00210-023-02839-1 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 22.11.2023. Verfasst von Abedeh Rezaei und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Biology¸ Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. Hauptthemen laut MEDLINE: Minocycline, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 138 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Minocycline is an FDA-approved secondary-generation tetracycline antibiotic. It is a synthetic antibiotic having many biological effects, such as antioxidant, anti-inflammatory, anti-cancer, and neuroprotective functions. This study discusses the pharmacological mechanisms of preventive and therapeutic effects of minocycline. Specifically, it provides a comprehensive overview of the molecular pathways by which minocycline acts on the different cancers, including ovarian, breast, glioma, colorectal, liver, pancreatic, lung, prostate, melanoma, head and neck, leukemia, and non-cancer diseases such as Alzheimer's disease, Parkinson, schizophrenia, multiple sclerosis, Huntington, polycystic ovary syndrome, and coronavirus disease 19. Minocycline may be a potential medication for these disorders due to its strong blood-brain barrier penetrance. It is also widely accepted as a specific medication, has a well-known side-effect characteristic, is reasonably priced, making it appropriate for continuous use in managing diseases, and has been demonstrated as an oral approach because it is effectively absorbed and accomplished almost all of the body's parts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MinocyclineNeoplasmsHumansAnimalsAntineoplastic AgentsAnti-Bacterial AgentsCOVID-19 Drug Treatment

Stichwörter der Autor:innen

Anti-cancerAnti-inflammatory effectCancerMinocyclineMolecular pathwayNeuroprotective effect

Substanzen

MinocyclineAntineoplastic AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Animal Biology¸ Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
  • Department of Animal Biology¸ Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. khalaj@tabrizu.ac.ir.

ORCID-Profile: Abedeh Rezaei, Amin Moqadami, Mohammad Khalaj-Kondori

Zitieren

APA

Rezaei, A., Moqadami, A., & Khalaj-Kondori, M. (2024). Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(5), 2835-2848. https://doi.org/10.1007/s00210-023-02839-1

Vancouver

Rezaei A, Moqadami A, Khalaj-Kondori M. Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(5):2835-2848. doi:10.1007/s00210-023-02839-1

BibTeX
@article{Rezaei2024,
  author = {Rezaei, Abedeh and Moqadami, Amin and Khalaj-Kondori, Mohammad},
  title = {Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  volume = {397},
  number = {5},
  pages = {2835--2848},
  doi = {10.1007/s00210-023-02839-1}
}
Kostenlos starten →